Literature DB >> 12763687

Role of complement in the control of HIV dynamics and pathogenesis.

Heribert Stoiber1, Cornelia Speth, Manfred P Dierich.   

Abstract

In all ex vivo preparations of HIV tested so far, C3 fragments and, after seroconversion, antibodies were detected on the viral surface. This indicates that HIV survives complement-mediated lysis. The virus has adopted different protection mechanisms to keep complement activation under the threshold necessary to induce virolysis. Among them are complement regulatory proteins that remain functionally active on the surface of HIV and turn down the complement cascade and serum proteins with complement regulatory activities. Therefore, opsonized virions accumulate in HIV-infected individuals, and subsequently adhere to complement receptor (CR) expressing cells. Among them are B cells, which bind opsonized virus. Such bound virus is efficiently transferred to autologous T cells, which subsequently are infected. Other cells interacting via CR with opsonized HIV are follicular dendritic cells (FDC). As shown by ex vivo experiments, up to 80% of virus is bound to follicular dendritic cells through C3-CR interactions. In the brain, HIV is not only interacting with complement proteins, but is able to induce their expression. Thus, interaction of HIV with the complement system is a main mechanism for pathogenesis to AIDS, since retention of (complement-resistant) opsonized viral particles on cell surfaces via CRs occurs in different compartments in HIV-infected individuals, thereby promoting transmission of virus to other permissive cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12763687     DOI: 10.1016/s0264-410x(03)00203-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  25 in total

Review 1.  HIV-1 and the hijacking of dendritic cells: a tug of war.

Authors:  Marie Larsson
Journal:  Springer Semin Immunopathol       Date:  2005-01

2.  Identification of complement regulatory domains in vaccinia virus complement control protein.

Authors:  Jayati Mullick; John Bernet; Yogesh Panse; Sharanabasava Hallihosur; Akhilesh K Singh; Arvind Sahu
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

3.  Complement-coated antibody-transfer (CCAT); serum IgA1 antibodies intercept and transport C4 and C3 fragments and preserve IgG1 deployment (PGD).

Authors:  Robert J Boackle; Quang L Nguyen; Renata S Leite; Xiaofeng Yang; Jana Vesely
Journal:  Mol Immunol       Date:  2005-03-05       Impact factor: 4.407

4.  Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked.

Authors:  Michael Huber; Viktor von Wyl; Christoph G Ammann; Herbert Kuster; Gabriela Stiegler; Hermann Katinger; Rainer Weber; Marek Fischer; Heribert Stoiber; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

Review 5.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

6.  Plasma levels of soluble membrane attack complex are elevated despite viral suppression in HIV patients with poor immune reconstitution.

Authors:  T N Schein; T E Blackburn; S L Heath; S R Barnum
Journal:  Clin Exp Immunol       Date:  2019-09-08       Impact factor: 4.330

Review 7.  Complement and HIV-I infection/HIV-associated neurocognitive disorders.

Authors:  Fengming Liu; Shen Dai; Jennifer Gordon; Xuebin Qin
Journal:  J Neurovirol       Date:  2014-03-18       Impact factor: 2.643

8.  A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS.

Authors:  Weiguo Hu; Qigui Yu; Ningjie Hu; Daniel Byrd; Tohti Amet; Cecilia Shikuma; Bruce Shiramizu; Jose A Halperin; Xuebin Qin
Journal:  J Immunol       Date:  2009-12-02       Impact factor: 5.422

9.  Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization.

Authors:  Mohammad-Ali Jenabian; Héla Saïdi; Charlotte Charpentier; Hicham Bouhlal; Dominique Schols; Jan Balzarini; Thomas W Bell; Guido Vanham; Laurent Bélec
Journal:  AIDS Res Ther       Date:  2010-06-14       Impact factor: 2.250

10.  Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.

Authors:  C Moog; N Dereuddre-Bosquet; J-L Teillaud; M E Biedma; V Holl; G Van Ham; L Heyndrickx; A Van Dorsselaer; D Katinger; B Vcelar; S Zolla-Pazner; I Mangeot; C Kelly; R J Shattock; R Le Grand
Journal:  Mucosal Immunol       Date:  2013-04-17       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.